厄洛替尼-话题@MedSci - williamhill asia

#厄洛替尼#

39篇内容 | 1633人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2193222, encodeId=a2fa219322271, content=<a href='/topic/show?id=04b5839e6a9' target=_blank style='color:#2F92EE;'>#胰腺癌#</a> <a href='/topic/show?id=f19136915a9' target=_blank style='color:#2F92EE;'>#厄洛替尼#</a>, objectTitle=见识了，同时存在KRAS和EGFR基因突变的胰腺癌，用了肺癌的靶向药厄洛替尼还管用！, objectType=article, longId=816138, objectId=1dc9816138a6, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/Random/young-people-on-medical-staff-meeting-ZFY96R4.jpg, objectUrl=/article/show_article.do?id=1dc9816138a6, replyNumber=0, likeNumber=60, createdTime=2024-03-14, rootId=0, userName=williamhill asia 管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=1dc9816138a6, moduleTitle=见识了，同时存在KRAS和EGFR基因突变的胰腺癌，用了肺癌的靶向药厄洛替尼还管用！, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=1dc9816138a6)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2193220, encodeId=9ae82193220e5, content=<a href='/topic/show?id=f6a9111224f4' target=_blank style='color:#2F92EE;'>#胰腺腺癌#</a> <a href='/topic/show?id=f19136915a9' target=_blank style='color:#2F92EE;'>#厄洛替尼#</a>, objectTitle=Mol Cancer：上海交通大学崔玖洁/王理伟等团队合作发现胰腺腺癌对厄洛替尼增敏的潜在新策略, objectType=article, longId=817086, objectId=ecb481e08647, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/Random/doctor-working-in-a-hospital-PSQT2U3.jpg, objectUrl=/article/show_article.do?id=ecb481e08647, replyNumber=0, likeNumber=44, createdTime=2024-03-14, rootId=0, userName=williamhill asia 管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=ecb481e08647, moduleTitle=Mol Cancer：上海交通大学崔玖洁/王理伟等团队合作发现胰腺腺癌对厄洛替尼增敏的潜在新策略, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=ecb481e08647)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=1332090, encodeId=b47b13320903a, content=<a href='/topic/show?id=f19136915a9' target=_blank style='color:#2F92EE;'>#厄洛替尼#</a>, objectTitle=Thorac Cancer：EGFR敏感突变NSCLC患者一线阿法替尼，吉非替尼或厄洛替尼治疗的生存获益比较, objectType=article, longId=728900, objectId=2d14e28900af, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2d14e28900af, replyNumber=0, likeNumber=53, createdTime=2022-06-10, rootId=0, userName=ms306040998833292, userId=d3572500071, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2d14e28900af, moduleTitle=Thorac Cancer：EGFR敏感突变NSCLC患者一线阿法替尼，吉非替尼或厄洛替尼治疗的生存获益比较, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=2d14e28900af)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1332089, encodeId=5185133208956, content=<a href='/topic/show?id=f19136915a9' target=_blank style='color:#2F92EE;'>#厄洛替尼#</a>, objectTitle=Transl Lung Cancer Res: 广医一院团队：第一代EGFR-TKIs(吉非替尼、厄洛替尼和埃克替尼)术后辅助治疗NSCLC伴有EGFR敏感突变患者的疗效比较, objectType=article, longId=295260, objectId=94052952604f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=94052952604f, replyNumber=0, likeNumber=0, createdTime=2022-02-09, rootId=0, userName=ms306040998833292, userId=d3572500071, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=94052952604f, moduleTitle=Transl Lung Cancer Res: 广医一院团队：第一代EGFR-TKIs(吉非替尼、厄洛替尼和埃克替尼)术后辅助治疗NSCLC伴有EGFR敏感突变患者的疗效比较, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=94052952604f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1332088, encodeId=212d13320886b, content=<a href='/topic/show?id=f19136915a9' target=_blank style='color:#2F92EE;'>#厄洛替尼#</a>, objectTitle=延长吉非替尼或厄洛替尼给药间隔时间治疗肺腺癌12例, objectType=article, longId=220727, objectId=e0d0220e277b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e0d0220e277b, replyNumber=0, likeNumber=60, createdTime=2021-11-23, rootId=0, userName=ms306040998833292, userId=d3572500071, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e0d0220e277b, moduleTitle=延长吉非替尼或厄洛替尼给药间隔时间治疗肺腺癌12例, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=e0d0220e277b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1332087, encodeId=9a68133208e7a, content=<a href='/topic/show?id=f19136915a9' target=_blank style='color:#2F92EE;'>#厄洛替尼#</a>, objectTitle=Lancet Respir Med：3期| 厄洛替尼+贝伐单抗未能延长转移性EGFR突变NSCLC患者的总生存期, objectType=article, longId=217099, objectId=442f21e09939, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=442f21e09939, replyNumber=0, likeNumber=70, createdTime=2021-09-16, rootId=0, userName=ms306040998833292, userId=d3572500071, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=442f21e09939, moduleTitle=Lancet Respir Med：3期| 厄洛替尼+贝伐单抗未能延长转移性EGFR突变NSCLC患者的总生存期, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=442f21e09939)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1332086, encodeId=1ad11332086e3, content=<a href='/topic/show?id=f19136915a9' target=_blank style='color:#2F92EE;'>#厄洛替尼#</a>, objectTitle=Lung Cancer：多西他赛vs多西他赛+厄洛替尼治疗复发晚期非鳞状非小细胞肺癌的疗效：III期临床研究NVALT-18, objectType=article, longId=216915, objectId=e8b0216915a0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e8b0216915a0, replyNumber=0, likeNumber=68, createdTime=2021-09-12, rootId=0, userName=ms306040998833292, userId=d3572500071, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e8b0216915a0, moduleTitle=Lung Cancer：多西他赛vs多西他赛+厄洛替尼治疗复发晚期非鳞状非小细胞肺癌的疗效：III期临床研究NVALT-18, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=e8b0216915a0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1332085, encodeId=81d1133208509, content=<a href='/topic/show?id=f19136915a9' target=_blank style='color:#2F92EE;'>#厄洛替尼#</a>, objectTitle=Clin cancer res：绿茶多酚E联合厄洛替尼可有效预防头颈部癌前病变恶变成癌, objectType=article, longId=201947, objectId=15c320194e43, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=15c320194e43, replyNumber=0, likeNumber=66, createdTime=2020-10-12, rootId=0, userName=ms306040998833292, userId=d3572500071, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=15c320194e43, moduleTitle=Clin cancer res：绿茶多酚E联合厄洛替尼可有效预防头颈部癌前病变恶变成癌, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=15c320194e43)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1332084, encodeId=5a5b13320843c, content=<a href='/topic/show?id=f19136915a9' target=_blank style='color:#2F92EE;'>#厄洛替尼#</a>, objectTitle=Br J Cancer：III期临床试验：选择性淋巴结照射和或厄洛替尼联合放化疗改善局部晚期食道鳞状细胞癌患者长期生存率, objectType=article, longId=201182, objectId=099320118291, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=099320118291, replyNumber=0, likeNumber=38, createdTime=2020-09-26, rootId=0, userName=ms306040998833292, userId=d3572500071, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=099320118291, moduleTitle=Br J Cancer：III期临床试验：选择性淋巴结照射和或厄洛替尼联合放化疗改善局部晚期食道鳞状细胞癌患者长期生存率, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=099320118291)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1332083, encodeId=7421133208389, content=<a href='/topic/show?id=f19136915a9' target=_blank style='color:#2F92EE;'>#厄洛替尼#</a>, objectTitle=ASCO 2020 | 19.4个月！雷莫卢单抗联合厄洛替尼黑马亮相, objectType=article, longId=195229, objectId=29d0195229fb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=29d0195229fb, replyNumber=0, likeNumber=0, createdTime=2020-06-05, rootId=0, userName=ms306040998833292, userId=d3572500071, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=29d0195229fb, moduleTitle=ASCO 2020 | 19.4个月！雷莫卢单抗联合厄洛替尼黑马亮相, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=29d0195229fb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1332082, encodeId=a9a61332082c7, content=<a href='/topic/show?id=f19136915a9' target=_blank style='color:#2F92EE;'>#厄洛替尼#</a>, objectTitle=AACR 2020：厄洛替尼±雷莫芦单抗一线治疗NSCLC EGFR突变III期研究的NGS下结果(RELAY研究), objectType=article, longId=193163, objectId=3f4219316311, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3f4219316311, replyNumber=0, likeNumber=60, createdTime=2020-05-01, rootId=0, userName=ms306040998833292, userId=d3572500071, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3f4219316311, moduleTitle=AACR 2020：厄洛替尼±雷莫芦单抗一线治疗NSCLC EGFR突变III期研究的NGS下结果(RELAY研究), moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=3f4219316311)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1332081, encodeId=13e013320817c, content=<a href='/topic/show?id=f19136915a9' target=_blank style='color:#2F92EE;'>#厄洛替尼#</a>, objectTitle=贝伐珠单抗（A）联合厄洛替尼（T）与厄洛替尼（T）单药有望成为EGFRm+ NSCLC突变晚期非小细胞肺癌一线治疗新标准, objectType=article, longId=180959, objectId=d44c18095907, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d44c18095907, replyNumber=0, likeNumber=60, createdTime=2019-10-13, rootId=0, userName=ms306040998833292, userId=d3572500071, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d44c18095907, moduleTitle=贝伐珠单抗（A）联合厄洛替尼（T）与厄洛替尼（T）单药有望成为EGFRm+ NSCLC突变晚期非小细胞肺癌一线治疗新标准, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=d44c18095907)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1332080, encodeId=24a113320806f, content=<a href='/topic/show?id=f19136915a9' target=_blank style='color:#2F92EE;'>#厄洛替尼#</a>, objectTitle=JCO：EGFR突变非小细胞肺癌患者接受厄洛替尼辅助治疗可以改善预后, objectType=article, longId=154705, objectId=7bee154e0525, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7bee154e0525, replyNumber=0, likeNumber=57, createdTime=2018-12-01, rootId=0, userName=ms306040998833292, userId=d3572500071, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7bee154e0525, moduleTitle=JCO：EGFR突变非小细胞肺癌患者接受厄洛替尼辅助治疗可以改善预后, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=7bee154e0525)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1332079, encodeId=d8a213320e908, content=<a href='/topic/show?id=f19136915a9' target=_blank style='color:#2F92EE;'>#厄洛替尼#</a>, objectTitle=CLIN CANCER RES：贝伐单抗联合厄洛替尼对结直肠癌的疗效与RAS状态无关, objectType=article, longId=140511, objectId=0541140511e7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0541140511e7, replyNumber=0, likeNumber=75, createdTime=2018-06-13, rootId=0, userName=ms306040998833292, userId=d3572500071, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0541140511e7, moduleTitle=CLIN CANCER RES：贝伐单抗联合厄洛替尼对结直肠癌的疗效与RAS状态无关, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=0541140511e7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1332078, encodeId=d40c13320e843, content=<a href='/topic/show?id=f19136915a9' target=_blank style='color:#2F92EE;'>#厄洛替尼#</a>, objectTitle=PLos One：miR-133b高表达与非小细胞肺癌中使用厄洛替尼作为二三线治疗的疗效较好相关, objectType=article, longId=136580, objectId=a8c613658085, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a8c613658085, replyNumber=0, likeNumber=77, createdTime=2018-04-28, rootId=0, userName=ms306040998833292, userId=d3572500071, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a8c613658085, moduleTitle=PLos One：miR-133b高表达与非小细胞肺癌中使用厄洛替尼作为二三线治疗的疗效较好相关, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=a8c613658085)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1332077, encodeId=5bf113320e794, content=<a href='/topic/show?id=f19136915a9' target=_blank style='color:#2F92EE;'>#厄洛替尼#</a>, objectTitle=EUR J Cancer：淋巴结照射和厄洛替尼治疗食管鳞状细胞癌, objectType=article, longId=131022, objectId=04661310224f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=04661310224f, replyNumber=0, likeNumber=56, createdTime=2018-03-02, rootId=0, userName=ms306040998833292, userId=d3572500071, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=04661310224f, moduleTitle=EUR J Cancer：淋巴结照射和厄洛替尼治疗食管鳞状细胞癌, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=04661310224f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1332076, encodeId=392813320e6a1, content=<a href='/topic/show?id=f19136915a9' target=_blank style='color:#2F92EE;'>#厄洛替尼#</a>, objectTitle=J Thorac Oncol：Tivantinib+厄洛替尼一线治疗EGFR突变NSCLC： MARQUEE研究亚组分析, objectType=article, longId=129878, objectId=0b251298e8ac, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0b251298e8ac, replyNumber=0, likeNumber=75, createdTime=2018-02-15, rootId=0, userName=ms306040998833292, userId=d3572500071, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0b251298e8ac, moduleTitle=J Thorac Oncol：Tivantinib+厄洛替尼一线治疗EGFR突变NSCLC： MARQUEE研究亚组分析, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=0b251298e8ac)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1332075, encodeId=3ba313320e529, content=<a href='/topic/show?id=f19136915a9' target=_blank style='color:#2F92EE;'>#厄洛替尼#</a>, objectTitle=EUR J Cancer：独立于EGFR的Elk1 / CIP2A信号介导了厄洛替尼衍生物TD52对三阴性乳腺癌细胞的凋亡诱导作用, objectType=article, longId=125226, objectId=585212522636, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=585212522636, replyNumber=0, likeNumber=62, createdTime=2018-01-02, rootId=0, userName=ms306040998833292, userId=d3572500071, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=585212522636, moduleTitle=EUR J Cancer：独立于EGFR的Elk1 / CIP2A信号介导了厄洛替尼衍生物TD52对三阴性乳腺癌细胞的凋亡诱导作用, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=585212522636)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1332074, encodeId=5d1813320e441, content=<a href='/topic/show?id=f19136915a9' target=_blank style='color:#2F92EE;'>#厄洛替尼#</a>, objectTitle=Sci Rep：一种基于色酮的STAT3抑制剂Erasin，在厄洛替尼耐药的肺癌细胞中诱导凋亡, objectType=article, longId=125082, objectId=eead1250826d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=eead1250826d, replyNumber=0, likeNumber=55, createdTime=2017-12-31, rootId=0, userName=ms306040998833292, userId=d3572500071, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=eead1250826d, moduleTitle=Sci Rep：一种基于色酮的STAT3抑制剂Erasin，在厄洛替尼耐药的肺癌细胞中诱导凋亡, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=eead1250826d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1332073, encodeId=373f13320e38b, content=<a href='/topic/show?id=f19136915a9' target=_blank style='color:#2F92EE;'>#厄洛替尼#</a>, objectTitle=CLIN CANCER RES：Lumretuzumab联合西妥昔单抗或厄洛替尼治疗实体肿瘤, objectType=article, longId=113721, objectId=8ede113e21b9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8ede113e21b9, replyNumber=0, likeNumber=73, createdTime=2017-09-24, rootId=0, userName=ms306040998833292, userId=d3572500071, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8ede113e21b9, moduleTitle=CLIN CANCER RES：Lumretuzumab联合西妥昔单抗或厄洛替尼治疗实体肿瘤, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=8ede113e21b9)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] williamhill asia 话题小助手

厄洛替尼

2020-05-29

williamhill asia 管理员 (审核中...)

前往app查看评论内容

#胰腺癌# #厄洛替尼#

见识了，同时存在KRAS和EGFR基因突变的胰腺癌，用了肺癌的靶向药厄洛替尼还管用！

2024-03-14发表于上海

williamhill asia 管理员 (审核中...)

前往app查看评论内容

#胰腺腺癌# #厄洛替尼#

Mol Cancer：上海交通大学崔玖洁/王理伟等团队合作发现胰腺腺癌对厄洛替尼增敏的潜在新策略

2024-03-14发表于上海

ms306040998833292 (审核中...)

前往app查看评论内容

#厄洛替尼#

Thorac Cancer：EGFR敏感突变NSCLC患者一线阿法替尼，吉非替尼或厄洛替尼治疗的生存获益比较

2022-06-10

ms306040998833292 (审核中...)

前往app查看评论内容

#厄洛替尼#

Transl Lung Cancer Res: 广医一院团队：第一代EGFR-TKIs(吉非替尼、厄洛替尼和埃克替尼)术后辅助治疗NSCLC伴有EGFR敏感突变患者的疗效比较

2022-02-09

ms306040998833292 (审核中...)

前往app查看评论内容

#厄洛替尼#

延长吉非替尼或厄洛替尼给药间隔时间治疗肺腺癌12例

2021-11-23

ms306040998833292 (审核中...)

前往app查看评论内容

#厄洛替尼#

Lancet Respir Med：3期| 厄洛替尼+贝伐单抗未能延长转移性EGFR突变NSCLC患者的总生存期

2021-09-16

ms306040998833292 (审核中...)

前往app查看评论内容

#厄洛替尼#

Lung Cancer：多西他赛vs多西他赛+厄洛替尼治疗复发晚期非鳞状非小细胞肺癌的疗效：III期临床研究NVALT-18

2021-09-12

ms306040998833292 (审核中...)

前往app查看评论内容

#厄洛替尼#

Clin cancer res：绿茶多酚E联合厄洛替尼可有效预防头颈部癌前病变恶变成癌

2020-10-12

ms306040998833292 (审核中...)

前往app查看评论内容

#厄洛替尼#

Br J Cancer：III期临床试验：选择性淋巴结照射和或厄洛替尼联合放化疗改善局部晚期食道鳞状细胞癌患者长期生存率

2020-09-26

ms306040998833292 (审核中...)

前往app查看评论内容

#厄洛替尼#

ASCO 2020 | 19.4个月！雷莫卢单抗联合厄洛替尼黑马亮相

2020-06-05

ms306040998833292 (审核中...)

前往app查看评论内容

#厄洛替尼#

AACR 2020：厄洛替尼±雷莫芦单抗一线治疗NSCLC EGFR突变III期研究的NGS下结果(RELAY研究)

2020-05-01

ms306040998833292 (审核中...)

前往app查看评论内容

#厄洛替尼#

贝伐珠单抗（A）联合厄洛替尼（T）与厄洛替尼（T）单药有望成为EGFRm+ NSCLC突变晚期非小细胞肺癌一线治疗新标准

2019-10-13

ms306040998833292 (审核中...)

前往app查看评论内容

#厄洛替尼#

JCO：EGFR突变非小细胞肺癌患者接受厄洛替尼辅助治疗可以改善预后

2018-12-01

ms306040998833292 (审核中...)

前往app查看评论内容

#厄洛替尼#

CLIN CANCER RES：贝伐单抗联合厄洛替尼对结直肠癌的疗效与RAS状态无关

2018-06-13

ms306040998833292 (审核中...)

前往app查看评论内容

#厄洛替尼#

PLos One：miR-133b高表达与非小细胞肺癌中使用厄洛替尼作为二三线治疗的疗效较好相关

2018-04-28

ms306040998833292 (审核中...)

前往app查看评论内容

#厄洛替尼#

EUR J Cancer：淋巴结照射和厄洛替尼治疗食管鳞状细胞癌

2018-03-02

ms306040998833292 (审核中...)

前往app查看评论内容

#厄洛替尼#

J Thorac Oncol：Tivantinib+厄洛替尼一线治疗EGFR突变NSCLC： MARQUEE研究亚组分析

2018-02-15

ms306040998833292 (审核中...)

前往app查看评论内容

#厄洛替尼#

EUR J Cancer：独立于EGFR的Elk1 / CIP2A信号介导了厄洛替尼衍生物TD52对三阴性乳腺癌细胞的凋亡诱导作用

2018-01-02

ms306040998833292 (审核中...)

前往app查看评论内容

#厄洛替尼#

Sci Rep：一种基于色酮的STAT3抑制剂Erasin，在厄洛替尼耐药的肺癌细胞中诱导凋亡

2017-12-31

ms306040998833292 (审核中...)

前往app查看评论内容

#厄洛替尼#

CLIN CANCER RES：Lumretuzumab联合西妥昔单抗或厄洛替尼治疗实体肿瘤

2017-09-24

科室
- - 订阅+
  - 更多科室
工具
服务